Piwi genes are not required for marrow HSC engraftment following irradiation.

<p>(A) Illustration of competitive transplantation scheme whereby the triple piwi mutant or control donor CD45.2⁺ bone marrow is mixed equally with competitor CD45.1⁺ bone marrow and injected into a cohort of lethally irradiated CD45.1⁺ wild-type recipient mice. (B) Percentages of donor-derived (CD45.2⁺) cells from the triple knockout (blue circle) and control (black triangle) donors in the peripheral blood of lethally irradiated CD45.1⁺ recipient mice, measured up to five months (22 weeks) after transplant. (C-E) Ratio of donor/recipient (CD45.2⁺/CD45.2⁻ ) derived cells within committed blood cell lineages, (C) T-cell (CD3⁺), (D) B-cell (B220⁺), and (E) myeloid cells (CD11b⁺). Data is the average of two independent experiments with 10 triple <i>Piwi</i> mutant injected recipients and 8 control injected recipients from each experiment. Each data point represents the mean ±SEM of 8–10 recipient mice, per donor genotype.